Clinical trial
Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
NCT01246986 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of LY2157299 in Patients With Hepatocellular Carcinoma
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 30, 2011
- Completion date
- December 24, 2019
- Enrollment
- 204 (actual)
- Sites
- 40
Conditions
As the registry lists them; a condition with its own page is linked.